At a glance
ClinicalIndex Comparison RecordN/ACompleted· 1,285 enrolled
Drug / intervention
non-interventionalother
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
POLARIS: PALBOCICLIB IN HORMONE RECEPTOR POSITIVE ADVANCED BREAST CANCER: A PROSPECTIVE MULTICENTER NON-INTERVENTIONAL STUDY
In Brief
An observational study evaluating non-interventional for Advanced Breast Cancer and Metastatic Breast Cancer. Completed, enrolled 1,285 participants across 305 sites in 2 countries.
Detailed Summary
This Non-Interventional Study will describe and analyze the clinical use of palbociclib in routine clinical practice in the treatment of advanced breast cancer.
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsAdvanced Breast Cancer, Metastatic Breast Cancer
CountriesCanada, United States
Collaborators--
Timeline
N/ACompletedFinished
2017201820192020202120222023202420252026
Enrollment StartJan 2017
First PostedSep 2017
Primary CompletionOct 2022
Study CompletionDec 2022
TodayJul 2026
First PostedSep 12, 2017
Enrollment StartJan 4, 2017
Primary CompletionOct 1, 2022
Study CompletionDec 22, 2022
TodayJul 2, 2026
Enrollment to primary: 5.7 yearsPosted 8.8 years ago
Interventions
non-interventionalother